Nobivac FELV

Nobivac FELV.

Presentation

The inactivated vaccine contains 102 microgram per ml of purified p45 FeLV-envelope antigen, obtained by genetic recombination of a strain of E. coli. The antigenic suspension is adjuvanted with 0.1 ml of a 3% aluminium hydroxide gel and with 10 microgram purified extract of Quillaja saponaria.

Uses

For active immunisation of healthy cats to prevent persistent feline leukaemia virus viraemia and any associated clinical signs. The onset of protection begins 2 weeks after immunisation and the duration of protection lasts one year after the primary vaccination course.

Dosage and administration

Shake the vial before use. Administer via the subcutaneous route 1 dose of Nobivac FeLV according to the following protocol.

Basic vaccination scheme

A first injection in cats from minimum 8 weeks of age.

A second injection in cats 3 to 4 weeks later.

Revaccination scheme

Annual revaccination.

Nobivac FeLV can be used to reconstitute 1 dose (1 vial) of cat vaccines in the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain) immediately prior to use by the addition of the contents of 1 vial (1 ml) Nobivac FeLV.

Contra-indications, warnings, etc

Since no data have been generated, do not use to vaccinate females during pregnancy and lactation.

Transient mild skin thickening or nodule formation, approximately 5-10 mm in size, may be observed at the injection site and disappear within 2 to 6 weeks without treatment. Occasionally systemic reactions (hyperthermia, anorexia, lethargy) may occur within one or two days after vaccine administration.

Where Nobivac FeLV has been used to reconstitute cat vaccines in the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain) prior to inoculation, a small, painless nodule at the site of vaccination is frequently observed. It can persist for up to 18 days post inoculation. Occasionally the nodule may be painful for up to 6 days after injection. A transient rise in body temperature or lameness may occur and last for up to 3 days post vaccination. In some cases, a slight dullness or reduced appetite may be observed for up to 1 day post vaccination.

In the rare event of hypersensitivity reaction following vaccination, administer an antihistamine, corticosteroid or adrenaline without delay and by the most immediate route.

No undesirable effects have been seen after the administration of an overdose of Nobivac FeLV except those indicated above.

The vaccine should be administered in accordance with the usual aseptic conditions for vaccination.

Vaccinate only healthy animals.

It is recommended that animals be treated for intestinal parasites at least 10 days prior to vaccination.

Safety and /or efficacy data are available which demonstrate that this vaccine can be mixed with cat vaccines in the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain).

Do not mix with other medicinal products except cat vaccines in the Nobivac range containing feline calicivirus (F9 strain), feline rhinotracheitis virus (G2620A strain) and/or feline panleucopenia virus (MW-1 or Bristol strain).

Nobivac FeLV has been developed by genetic engineering technology which allows for the production of the single specific antigen responsible for the stimulation of full immunity to all components of FeLV disease. This antigen is sub-group A FeLV p45 which is the specific fraction of the envelope glycoprotein gp70 involved in the immune process. In field conditions, only sub-group A of FeLV is infective and once established in the cat's body it leads to the production of sub-groups B, C and FOCMA. By concentrating only sub-group A p45 in the vaccine, full protection is achieved with no danger of infection or immuno-suppression resulting from the inclusion of other viral components in the vaccine.

Operator warnings

In the case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Withdrawal period

Not applicable.

For animal treatment only. Keep out of the reach and sight of children.

Pharmaceutical precautions

Store and transport in the original package at a temperature of 4°C ± 2°C and away from light.

Do not freeze.

Keep container in the outer carton.

Any unused product or waste material should be disposed of in accordance with national requirements.

Legal category

POM-V

Packaging Quantities

Cardboard boxes containing 10 or 50 single dose vials of vaccine.

Not all presentations may be marketed.